<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article76</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/EXCEL" style="display:block; margin-bottom:10px;">EXCEL Original</a></li>
<h2><strong>EXCEL</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease". The New England Journal of Medicine. 2016. 375:2223-35. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with obstructive left main coronary artery disease of low or intermediate anatomical complexity, is percutaneous coronary intervention (PCI) with fluoropolymer-based cobalt–chromium everolimus-eluting stents noninferior to coronary-artery bypass grafting (CABG)?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with left main coronary artery disease of low or intermediate anatomical complexity, PCI with everolimus-eluting stents was noninferior to CABG with respect to the composite end point of death, stroke, or myocardial infarction at 3 years.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
European and U.S. guidelines recommend most patients with left main coronary artery disease undergo CABG. PCI with drug-eluting stents might be an acceptable alternative for selected patients.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, open-label, randomized trial<br/>
- N=1,905 patients with left main coronary artery disease<br/>
- PCI with everolimus-eluting stents (n=948)<br/>
- CABG (n=957)<br/>
- Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) score ≤32<br/>
- Setting: 126 sites in 17 countries<br/>
- Enrollment: 2010-2014<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Composite of death from any cause, stroke, or myocardial infarction at 3 years<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Stenosis of left main coronary artery ≥70% visually estimated, or 50% to &lt;70% with hemodynamic significance determined by noninvasive or invasive testing<br/>
- Anatomical complexity of coronary artery disease, defined by SYNTAX score ≤32<br/>
- CABG or PCI candidacy confirmed by a heart team<br/>
<br/>
Exclusion Criteria:<br/>
- SYNTAX score &gt;32<br/>
<br/>
Baseline Characteristics:<br/>
- Well balanced between groups<br/>
- SYNTAX score: Low (≤22) in 60.5%, intermediate (23-32) in 39.5%<br/>
- Distal left main bifurcation/trifurcation disease: 80.5%<br/>
- Two-vessel or three-vessel disease: 51.3%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- PCI goal: Complete revascularization of all ischemic territories<br/>
- CABG goal: Complete anatomical revascularization of all vessels ≥1.5 mm with angiographic diameter stenosis ≥50%<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes:<br/>
- Composite of death, stroke, or MI at 3 years occurred in 15.4% (PCI) vs. 14.7% (CABG) (noninferiority margin, 4.2 percentage points; P=0.02 for noninferiority)<br/>
<br/>
Secondary Outcomes:<br/>
- Composite of death, stroke, or MI at 30 days: 4.9% (PCI) vs. 7.9% (CABG) (P&lt;0.001 for noninferiority, P=0.008 for superiority)<br/>
- Composite of death, stroke, MI, or ischemia-driven revascularization at 3 years: 23.1% (PCI) vs. 19.1% (CABG) (P=0.01 for noninferiority)<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Abbott Vascular<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
